The DOI matches its Crossref record.
Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction
Abstract
Sir—Since the publication of our manuscript, “Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor antagonists” [1], we have learned that we inadvertently included foreign adverse event reports in our calculations. We regret this error. We also have been informed that Centocor has modified its method of calculating the total number of patients treated with infliximab (Remicade) in the United States, reducing slightly the estimate for the period of the report, from 233,000 patients to 197,000 patients. On the basis of these data, the rates of tuberculosis (TB) due to infliximab and etanercept use in the United States are 54 and 28 cases per 100,000 treated patients, respectively (P < .0001, by Poisson analysis [2]). Histoplasmosis, coccidioidomycosis, and listeriosis also occurred significantly more often with infliximab use. The corrected analysis appears in table 1. A major conclusion of our study [1] was that the risk of reactivation of TB was greater with infliximab than with etanercept. We postulated that these drugs had differential effects on preexisting granulomas that were based on differences in their mechanisms of action. Other conditions that impair mycobacterial immunity also increase the risk of disseminated or extrapulmonary disease and shorten the time to onset. Unlike incidence rates, these parameters are not readily compromised by incomplete reporting. We therefore sought to validate our analysis by examining time to onset of tuberculosis (TB) and extent of dissemination with use of the most recent data set released by the US Food and Drug Administration. This analysis was not restricted to cases reported in the United States.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dixon, W. G., Hyrich, K. L., Watson, K. D., Lunt, M., Galloway, J., Ustianowski, A., & Symmons, D. P. M. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.118935 · Cited by 715
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot‐Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R. M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24632 · Cited by 632
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
Strangfeld, A. (2009) · JAMA · doi:10.1001/jama.2009.146 · Cited by 542
Solovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00028510 · Cited by 527
Self-citation
Metadata
- Authors
- Wallis, R. S., Broder, M., Wong, J., & Beenhouwer, D.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-10-15
- Volume
- 39
- Issue
- 8
- Pages
- 1254-1255
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2073713475
- Cited by
- 219
- References
- 0
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction. https://app.cochat.ai/papers/10.1086/424455
- The paper
- Wallis, R. S., Broder, M., Wong, J., & Beenhouwer, D. (2004). Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction. Clinical Infectious Diseases. https://doi.org/10.1086/424455
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.